When was Singulex founded?

Singulex was founded in 1997 and raised its 1st funding round 5 years after it was founded.

Where is Singulex located?

Singulex is headquartered in Alameda, United States. It is registered at Alameda, California.

How many employees does Singulex have?

As of Mar 01, 2026, the latest employee count at Singulex is 200 - 499.

Is Singulex a funded company?

Singulex is a funded company, having raised a total of $141M across 16 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 23, 2002.

How much is Singulex worth?

The latest valuation of Singulex is $***** as of Mar 14, 2012.

When was the latest funding round of Singulex?

Singulex's latest funding was a $***** Conventional Debt round on Apr 17, 2017, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.75B in funding in 2026 to date.

Where does Singulex rank among its competitors?

Singulex ranks 29th amongst 151 active competitors, of which 45 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of Singulex?

Singulex's top competitors include Tango Therapeutics, Seer and Maze Therapeutics. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

Singulex - 2026 Company Profile, Funding & Competitors

Company Details

Revolutionizing immunodiagnostics with ultra-sensitive technology to transform healthcare. Pioneering Next Generation Immunodiagnostics (NGI) with proprietary Single Molecule Counting (SMC) technology, enabling unprecedented precision in biomarker measurement. This ultra-sensitive accuracy provides definitive health status insights for physicians and patients, improving health outcomes and reducing healthcare costs. NGI commercial offerings are transforming patient care from reactive disease treatment to proactive health management. The company delivers SMC technology through its clinical lab and is launching a fully automated immuno-analyzer for cardiovascular, oncology, infectious disease, neurodegenerative, and autoimmune diagnostic products. The company focuses on clinical diagnostics, immunodiagnostics, healthcare solutions, and medical technology.

Website: www.singulex.com/
Social
Registered Address: Alameda, California

Key Metrics

Founded Year

1997

Location

Alameda, United States

Stage

Series G

Total Funding

$141M in 16 rounds

Latest Funding Round

Conventional Debt, Apr 17, 2017, $*****

Post Money Valuation

$***** as on Mar 14, 2012

Investors

Orbimed & 11 more

Ranked

29^th among 151 active competitors

Employee Count

200 - 499 as on Mar 01, 2026

Similar Companies

Tango Therapeutics & 189 more

View Singulex's full profile

Singulex is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
SINGULEX, INC. CIN: 4025368 , United States, Active	Dec 01, 2010	£0 - £1M (As on Dec 31, 2021)	-	-
SINGULEX, INC. CIN: 134213664 , United States, Active	Dec 26, 999	-	7 (As on Dec 31, 2019)	-

Singulex has raised a total funding of $141M over 16 rounds. Its first funding round was on Oct 23, 2002. Its latest funding round was a Conventional Debt round on Apr 17, 2017 for $*****. 1 investor participated in its latest round. Singulex has 12 institutional investors.

Here is the list of recent funding rounds of Singulex:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 17, 2017	3695502	Conventional Debt	8776099	6686692	7347754	6642241
May 31, 2016	8067196	Series G	2254421	9989618	8617664	Grifols
Sep 26, 2013	9419784	Conventional Debt	1616483	3590794	8782928	Oxford Finance & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Singulex's funding rounds and investors

Singulex's employee count trend

Singulex has 200 - 499 employees as of Mar 26. Here is Singulex's employee count trend over the years:

Uncover Singulex's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Singulex include Tango Therapeutics, Seer and Maze Therapeutics. Here is the list of Top 10 competitors of Singulex, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
2nd	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	68/100
3rd	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Matrix Capital Management, Frazier Life Sciences ... & 21 others	67/100
4th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	67/100
5th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, New Enterprise Associates ... & 3 others	65/100
6th	NanoCellect Biomedical 2009, San Diego (United States), Series D	Develops flow cytometry and cell sorting technology	$78.1M	Illumina Ventures, Vertical Venture Partners ... & 15 others	59/100
7th	Oxford Biodynamics 2007, Oxford (United Kingdom), Public	Developer of personalized diagnostics by identifying biomarkers through epigenetics	$11M	Armistice Capital, Oxford University Innovation ... & 1 others	58/100
8th	Denovo Biopharma 2013, San Diego (United States), Series D	Developer of genomic biomarker discovery platform	$172M	Guangzhou Yuexiu Industrial Investment Fund Management, CICC ... & 12 others	56/100
9th	LumaCyte 2012, Charlottesville (United States), Series B	Provider of microfluidic and optics based instruments	$24.1M	Malvern Panalytical, Asahi Kasei	54/100
10th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100
29th	Singulex 1997, Alameda (United States), Series G	Revolutionizing immunodiagnostics with ultra-sensitive technology to transform healthcare	$141M	Perceptive Advisors, Western Alliance Bank ... & 10 others	43/100